SeaStar Medical HoldingICU -3.40%29 Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus rates ICU with a GF Score™ of 29/100. The stock has 4 warning signs investors should review. Among 151 Biotechnology companies, SeaStar Medical Holding ranks worse than 662250.99% on this metric.
As of today (2026-06-26), the Trailing Annual Dividend Yield of SeaStar Medical Holding is 0.00%.
The historical rank and industry rank for SeaStar Medical Holding's Dividend Yield % or its related term are showing as below:
ICU's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.53 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
SeaStar Medical Holding (NAS:ICU) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU vs MBRX, LEXX, INTI: Dividend Yield % Comparison
For the Biotechnology subindustry, SeaStar Medical Holding's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SeaStar Medical Holding Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SeaStar Medical Holding's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where SeaStar Medical Holding's Dividend Yield % falls into.
SeaStar Medical Holding (ICU) has a Dividend Yield % of 0.00% as of Jun. 26, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on SeaStar Medical Holding and its competitors. According to the industry distribution chart, SeaStar Medical Holding ranks #999999 out of 151 companies in the Biotechnology industry.
Is SeaStar Medical Holding's Dividend Yield % too high?
SeaStar Medical Holding's current Dividend Yield % is 0.00%. Based on the distribution chart, SeaStar Medical Holding ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SeaStar Medical Holding has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does SeaStar Medical Holding's Dividend Yield % compare to MBRX and LEXX?
According to the Biotechnology industry distribution chart, SeaStar Medical Holding ranks #999999 out of 151 companies for Dividend Yield %. This places SeaStar Medical Holding in the lower half of its industry. The industry median Dividend Yield % is 1.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.53, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on SeaStar Medical Holding and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SeaStar Medical Holding's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SeaStar Medical Holding stock overvalued right now?
SeaStar Medical Holding (ICU) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. SeaStar Medical Holding's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For SeaStar Medical Holding (ICU), the current Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
29GF Score
Get the complete analysis for ICU
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICU has been successfully added to your 
